Your browser doesn't support javascript.
loading
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.
Maruapula, Dorcas; Moraka, Natasha O; Bareng, Ontlametse T; Mokgethi, Patrick T; Choga, Wonderful T; Seatla, Kaelo K; Kelentse, Nametso; Koofhethille, Catherine K; Zuze, Boitumelo J L; Gaolathe, Tendani; Pretorius-Holme, Molly; Makhema, Joseph; Novitsky, Vlad; Shapiro, Roger; Moyo, Sikhulile; Lockman, Shahin; Gaseitsiwe, Simani.
Afiliação
  • Maruapula D; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Moraka NO; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Bareng OT; Faculty of Health Sciences, Medical Laboratory Sciences, University of Botswana, Gaborone, Botswana.
  • Mokgethi PT; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Choga WT; Faculty of Health Sciences, Medical Laboratory Sciences, University of Botswana, Gaborone, Botswana.
  • Seatla KK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Kelentse N; Faculty of Science, Biological Sciences, University of Botswana, Gaborone, Botswana.
  • Koofhethille CK; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Zuze BJL; Faculty of Health Sciences, Medical Laboratory Sciences, University of Botswana, Gaborone, Botswana.
  • Gaolathe T; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Pretorius-Holme M; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Makhema J; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Novitsky V; Department of Immunology and Infectious Diseases, Harvard University T.H. Chan School of Public Health, Boston, MA, USA.
  • Shapiro R; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Moyo S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Lockman S; Department of Immunology and Infectious Diseases, Harvard University T.H. Chan School of Public Health, Boston, MA, USA.
  • Gaseitsiwe S; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
J Antimicrob Chemother ; 78(10): 2489-2495, 2023 10 03.
Article em En | MEDLINE | ID: mdl-37585352
OBJECTIVES: Pre-existing rilpivirine resistance-associated mutations (RVP-RAMs) have been found to predict HIV-1 virological failure in those switching to long-acting injectable cabotegravir/rilpivirine. We here evaluated the prevalence of archived RPV-RAMs in a cohort of people living with HIV (PWH). METHODS: We analysed near full-length HIV-1 pol sequences from proviral DNA for the presence of RPV-RAMs, which were defined according to the 2022 IAS-USA drug resistance mutation list and Stanford HIV drug resistance database. RESULTS: RPV-RAMs were identified in 757/5805 sequences, giving a prevalence of 13.0% (95% CI 12%-13.9%). Amongst the ART-naive group, 137/1281 (10.7%, 95% CI 9.1%-12.5%) had at least one RPV-RAM. Of the 4524 PWH with viral suppression on ART (VL <400 copies/mL), 620 (13.7%, 95% CI 12.7%-14.7%) had at least one RPV-RAM. E138A was the most prevalent RPV-RAM in the ART-naive group (7.9%) and the ART-suppressed group (9.3%). The rest of the mutations observed (L100I, K101E, E138G, E138K, E138Q, Y181C, H221Y, M230L, A98G, V179D, G190A, G190E and M230I) were below a prevalence of 1%. CONCLUSIONS: RPV-RAMs were present in 10.7% of ART-naive and 13.7% of ART-suppressed PWH in Botswana. The most common RPV-RAM in both groups was E138A. Since individuals with the E138A mutation may be more likely to fail cabotegravir/rilpivirine, monitoring RPV-RAMs will be crucial for effective cabotegravir/rilpivirine implementation in this setting.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Fármacos Anti-HIV Tipo de estudo: Risk_factors_studies Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Soropositividade para HIV / Fármacos Anti-HIV Tipo de estudo: Risk_factors_studies Limite: Humans País como assunto: Africa Idioma: En Ano de publicação: 2023 Tipo de documento: Article